NYSEHealth CareHealth Care EquipmentS&P MidCap 400
$319.21
-1.90 (-0.59%)
Close of Nov 06, 2026 · end-of-day data
PEN 8-K filings in 2026
Every material Form 8-K Penumbra filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Penumbra reported third quarter 2026 revenue of $410.1 million, representing a 15.6% increase compared to the third quarter of 2025. Net income for the quarter was $42.3 million, down from $45.9 million in the prior year period. Due to the pending acquisition by Boston Scientific Corporation, the company did not provide full-year 2026 financial guidance.
Revenue reached $410.1 million in the third quarter of 2026, up 15.6% year-over-year.
Global thrombectomy revenue grew 18.1% to $279.2 million for the quarter ended September 30, 2026.
Net income for the third quarter of 2026 was $42.3 million, yielding diluted net income per share of $1.07.
Operating expenses totaled $229.6 million, including $7.1 million in acquisition-related expenses tied to the pending Boston Scientific transaction.
Penumbra reported second-quarter 2026 revenue of $390.0 million, up 14.9% from a year earlier, but net income fell to $34.8 million from $45.3 million and diluted earnings per share dropped to $0.88 from $1.15. The company will not provide full-year 2026 guidance or hold a earnings call because of its pending acquisition by Boston Scientific Corporation, leaving shareholders without a current outlook.
Q2 2026 revenue was $390.0 million, up 14.9%; thrombectomy rose 12.5% to $259.0 million and embolization and access rose 20.0% to $131.1 million.
Q2 2026 net income was $34.8 million versus $45.3 million a year earlier; the provision for income taxes was $11.4 million compared with $40 thousand.
SG&A included $6.9 million of acquisition-related expenses tied to the pending acquisition by Boston Scientific Corporation, and no full-year 2026 financial guidance will be provided.
Penumbra reported first quarter 2026 revenue of $374.8 million, up 15.6% from a year earlier, but net income fell to $32.6 million from $39.2 million and diluted earnings per share fell to $0.82 from $1.00. The company will not provide full-year 2026 guidance or hold an earnings call because of its pending acquisition by Boston Scientific.
Revenue of $374.8 million, up 15.6%; thrombectomy up 12.1% to $253.9 million and embolization and access up 23.8% to $120.8 million
Net income of $32.6 million versus $39.2 million in Q1 2025; diluted EPS of $0.82 versus $1.00
$9.4 million of acquisition-related expenses included in SG&A, tied to the pending Boston Scientific acquisition
No full-year 2026 financial guidance and no conference call, due to the pending Boston Scientific acquisition
Penumbra reported fourth quarter 2025 revenue of $385.4 million, up 22.1%, and net income of $47.3 million, compared with $33.7 million a year earlier. Full-year 2025 revenue rose 17.5% to $1,403.7 million and net income reached $177.7 million, versus $14.0 million in 2024. The company will not provide 2026 financial guidance or hold a conference call because of its proposed acquisition by Boston Scientific.
Q4 2025 diluted EPS was $1.20, compared with $0.86 in Q4 2024.
Full-year 2025 income from operations was $189.2 million, compared with $9.3 million in 2024.
No financial guidance for full-year 2026 because of the proposed acquisition by Boston Scientific Corporation (NYSE: BSX).
Penumbra agreed on January 14, 2026 to merge with Boston Scientific, which will acquire it in a deal valued at $374 per share and an enterprise value of approximately $14.5 billion. The same day, Penumbra released preliminary fourth quarter and full year 2025 revenue that grew 17.3% to 17.5% for the year, and the merger requires Penumbra stockholder approval and other closing conditions.
Each Penumbra share can be exchanged for $374 in cash or 3.8721 Boston Scientific shares, subject to proration to about 73% cash and 27% stock.
Boston Scientific expects to finance the approximately $11 billion cash portion with cash on hand and new debt.
The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary conditions, and Penumbra stock would be delisted from the NYSE.
Preliminary full year 2025 revenue of $1,401.3 million to $1,403.1 million, up 17.3% to 17.5%; fourth quarter revenue of $383.0 million to $384.8 million, up 21.4% to 22.0%.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Penumbra filing is on SEC EDGAR ↗. 8-K briefs of other companies →